The European Pediatric Pulmonary Vascular Disease Network is a registered, non-profit organization that strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of pediatric pulmonary hypertensive vascular disease, including pulmonary hypertension (PH) associated with bronchopulmonary dysplasia, PH associated with congenital heart disease (CHD), persistent PH of the newborn, and related cardiac dysfunction. The executive writing group members conducted searches of the PubMed/MEDLINE bibliographic database (1990−2018) and held face-to-face and web-based meetings. Ten section task forces voted on the updated recommendations, based on the 2016 executive summary. Clinical trials, meta-analyses, guidelines, and other articles that include pediatric data were searched using the term "pulmonary hypertension" and other keywords. Class of recommendation (COR) and level of evidence (LOE) were assigned based on European Society of Cardiology/American Heart Association definitions and on pediatric data only, or on adult studies that included >10% children or studies that enrolled adults with CHD. New definitions by the World Symposium on Pulmonary Hypertension 2018 were included. We generated 10 tables with graded recommendations (COR/LOE). The topics include diagnosis/monitoring, genetics/biomarkers, cardiac catheterization, echocardiography, cardiac magnetic resonance/chest computed tomography, associated forms of PH, intensive care unit/lung transplantation, and treatment of pediatric PH. For the first time, a set of specific recommendations on the management of PH in middle-and low-income regions was developed. Taken together, these executive, up-to-date guidelines provide a specific, comprehensive, detailed but practical framework for the optimal clinical care of children and young adults with PH.
Pulmonary hypertension (PH) and associated pulmonary vascular disease (PVD) are characterized by pulmonary vascular remodeling leading to elevated pulmonary arterial pressure and, over time, right ventricular (RV) dysfunction, underfilling/compression of the left ventricle, and terminal heart failure. 1−3 PH-associated mortality has been decreasing over the last 2 decades in children 4 and adults, 5 likely because of increased awareness of this condition and its multiple etiologies, more accurate diagnosis, better risk stratification, and early initiation of combination pharmacotherapy. 3,5−7 Nevertheless, transplant-free survival of children and adults with idiopathic pulmonary arterial hypertension (IPAH), heritable pulmonary arterial hypertension (HPAH), and other forms of World Health Organization (WHO) Group 1 PH, such as Eisenmenger syndrome and persistent pulmonary arterial hypertension (PAH) after repair of congenital heart disease (CHD) (PAH-CHD) remains poor. 3, 4, 8, 9 Although there is currently no cure for PAH, both the established and experimental therapies aim to stop or even reverse disease progression, thereby relieving the significant morbidity and mortality and improving the patients' quality of life.
Rationale for the 2019 updated consensus on pediatric PH
The 2015 European Society of Cardiology (ESC) and European Respiratory Society guidelines on the diagnosis and treatment of PH includes comprehensive recommendations on the diagnosis and treatment of PH but mainly focuses on clinical care in adults. 10 Both a new definition and an expanded classification of PH were developed at the World Symposium on PH (WSPH, Nice, 2018) 11, 12 (Box 1 and 2;
Supplementary Tables S1, S2, and S3, available online at www.jhltonline.org). The unique features of pediatric PH were recognized for the first time at the 2013 WSPH, resulting in a dedicated short document on pediatric PH 13 that was recently updated. 12 Based on our previous expert consensus recommendations in 2016, 14 we deliver updated, comprehensive, practical guidelines for healthcare providers addressing the specifics of PH and PVD in children and young adults.
Objectives of the 2019 Consensus Statement of the European Pediatric PVD Network (EPPVDN)
In 2016, the EPPVDN published a multipaper consensus statement that contains practical recommendations for health care providers treating children and adolescents with different forms of PH. 14 The objectives of our 2019 guidelines on pediatric PH are the following: 1. To briefly discuss the most recent changes to the classification and definition of PH and its subtypes (World Symposium on PH in Nice 2018); 11,12 2. To outline clinical study results and their limitations; 3. To provide graded, evidence-based, and expert-based recommendations for optimal diagnosis and treatment of infants, children, and young adults with PH (including CHD/Eisenmenger and single ventricle physiology/ Fontan), according to the grading system provided by the American Heart Association and ESC; 4. To address features of the disease and its management that are specific to pediatric PH; 5. To define the multiple gaps in our knowledge on pediatric PH; and 6. To briefly discuss emerging PH therapies (safety and efficacy).
Methodology
Goals and composition of the EPPVDN's executive writing group (EWG)
The EPPVDN is a registered non-profit organization. The network strives to define and develop effective, innovative diagnostic methods and treatment options for all forms of pediatric PH and associated heart failure. The EWG members were recruited from Austria, Belgium, Germany, Finland, France, India, Italy, Pakistan, Sweden, Switzerland, the United Kingdom, and the United States of America. The EWG consisted of 22 pediatricians (with expertise and board certifications in pediatric cardiology, critical care, pulmonology, neonatology, sports medicine, and/or genetics), 7 doctors with subspecialty certifications for adults with CHD (3 adult cardiology, 4 pediatric cardiology), 1 adult pulmonologist, and 1 thoracic transplant surgeon.
Special features of the 2019 guidelines on pediatric PH
Previously, we followed a novel approach to develop 10 individual papers sorted by clinical topic, including "diagnosis/monitoring" 6 , "treatment" 7 , and an "executive summary" 14 , in a special issue on pediatric pulmonary hypertension (https://heart.bmj.com/content/ 102/Suppl_2). In these guidelines, status after the WSPH 2018 meeting, we updated and expanded the 2016 executive summary to develop the 2019 EPPVDN guidelines. The following disease-specific, complex, and common patient groups are addressed separately:
(1) PH associated with CHD, including recommendations for both children and young adults with PAH-CHD; and (2) persistent PH of the newborn (PPHN) and PH associated with bronchopulmonary dysplasia (BPD)/chronic lung disease (CLD) in infancy. The 2019 updated EPPVDN guidelines also give detailed recommendations on the treatment of acute PH in the intensive care unit, including extracorporeal membrane oxygenation and lung transplantation, and comprehensive recommendations on mid-to long-term treatment of PH in inpatient and outpatient settings, including pharmacotherapy, catheter interventions, and surgery. Moreover, for the first time, we highlight the challenges and special aspects of diagnostics and treatment of PH in middle to low income regions (MLIRs). This consensus document has been endorsed by the Association for European Pediatric and Congenital Cardiology (AEPC), the European Society for Pediatric Research (ESPR), and the International Society of Heart and Lung Transplantation (ISHLT).
Literature search
Searches of the PubMed/MEDLINE bibliographic database were conducted for the time period 1990−2018. Clinical studies/trials, guidelines, consensus statements, and reviews including pediatric data and/or adults with CHD were searched using the terms "pulmonary hypertension" and up to 10 other keywords. The primary focus of this manuscript is on group 1 PH, according to the WSPH in Nice, 2018. 11
Class of recommendation (COR) and level of evidence (LOE)
The COR and LOE grading was based on pediatric PH study data, adult PAH studies enrolling >10% children, or studies on children 
Class of recommendation Definition
Suggested wording to use Class I Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.
Is recommended/ is indicated Class II Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.
Class IIa
Weight of evidence/opinion is in favor of usefulness/efficacy. Should be considered Class IIb Usefulness/efficacy is less well Established by evidence/opinion.
May be considered
Class III Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.
Is not recommended AHA, American Heart Association; COR, class of recommendation; ESC European Society of Cardiology. The color coding was used throughout the 2019 Updated Guidelines on the Diagnosis and Treatment of Pediatric Pulmonary Hypertension-The European Pediatric Pulmonary Vascular Disease Network. 11 and the classification of pediatric PHVD 15 can be found in Supplementary Tables S1 and S2, respectively (available online). Details on hemodynamic definitions, invasive measures, and clinical implications are given in Supplementary Table S3 online. Detailed hemodynamic definitions of PH (e.g., value of the diastolic TPG) can be found in the 2015 ESC/ERS guidelines, 10 Hansmann (2017) 3 and Apitz et al.
(2016) 16 It should be noted that even mildly elevated mPAP values (20−24 mm Hg, prognostic threshold 17 mm Hg) are independent predictors of poor survival in adults with PH (Douschan et al., 2018) . 17 In adults, PVR is usually not indexed to BSA. a In many instances, it is useful to measure the PAWP simultaneously with LVEDP. b PVRI-Panama classification of pediatric PHVD, 2011 mPAP ≥ 25mm Hg used to define PH BSA, body surface area; Cpc-PH, combination of pre-capillary and post-capillary pulmonary hypertension; DPG, diastolic pulmonary gradient; ERS, European Respiratory Society ESC, European Society of Cardiology; HFpEF, heart failure with preserved ejection fraction; HPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension; Ipc-PH, isolated post-capillary pulmonary hypertension; LV, left ventricle; LVEDP, left ventricular end-diastolic pressure; mLAP, mean left atrial pressure; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PDA, patent ductus arteriosus; PH, pulmonary hypertension; PHVD, pulmonary hypertensive vascular disease; PVR, pulmonary vascular resistance; TPG, transpulmonary pressure gradient; VSD, ventricular septal defect; WSPH, World Symposium on Pulmonary Hypertension; WU, Wood units. and adults with PAH-CHD. Details on the ESC/American Heart Association grading system for COR (Table 1) and LOE (Table 2) , as well as the voting, peer review, and endorsement process, can be found in the Supplementary Material online. The supplement also includes additional text, figures, tables, and the supplementary references per section (ref. S3-1 to S12-26), as listed in numerical order in the graded recommendations (Tables 3−12) . Importantly, healthcare providers must adhere to the medication labeling and follow future drug recommendations/warnings potentially published by the European Medicines Agency and the US Food and Drug Administration when applying these recommendations in clinical practice.
Summary of graded recommendations by clinical topic
Diagnostics, monitoring, and outpatient care in children or young adults with suspected PH A diagnostic algorithm for a child or young adult with suspected PH can be found in Figure 1 . Here, we make recommendations on established and newly identified diagnostic and monitoring variables, tools, and procedures in pediatric PH (Table 3) . A new EPPVDN pediatric PH risk score sheet can be found in the Supplementary Material (Supplementary Figure S1 ). Further details and the technical and methodologic limitations of the diagnostic tools are discussed elsewhere. 6 
Transthoracic echocardiography in children with suspected PH
We focus our recommendations on newly developed key transthoracic echocardiography variables with according normal reference values including RV outflow tract size and flow, right atrial function, and pulmonary arterial acceleration time (Table 4 ). Special attention is given to relevant ventricular−ventricular interaction variables that are used to determine pressure, myocardial contractility, flow, and systolic and diastolic function of both ventricles. A detailed Box 2. What is new in the 2019 Updated EPPVDN Consensus Statement on Pediatric PH? 1. The WSPH 2018 modified the definition and classification of PH presented in the 2015 ESC/ERS Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension. 10 In particular, the lower limit of normal mPAP was decreased from 24 to 20 mm Hg. 11 Even mildly elevated mPAP values (20−24 mm Hg, prognostic threshold 17 mm Hg) were recently found to be independent predictors of poor survival in adults with PH. 17 For consistency, this new definition of PH was also used in the pediatric WSPH 2018 document 12 and our 2019 EPPVDN consensus statement, although the cut-off mPAP > 20 mm Hg remains arbitrary because no according prognostic pediatric data are available. 2. As in adults, a sub-group of children with IPAH can be identified who are positive responders to AVT and would now be classified as "PAH long-term responders to CCBs" according to the WSPH 2018 (Group 1.5 PH). 11 AVT is estimated to be positive in approximately 15−30% of children with IPAH, depending on the AVT criteria applied (Sitbon, 15%; modified Barst/pediatric REVEAL, 30%). Because only half of the adult responders have a long-term hemodynamic and clinical improvement on CCB therapy, close long-term follow-up is required, and combination therapy may be warranted once CCB monotherapy becomes partly inefficient. 3. PAH and PVOD/PCH are now considered a spectrum of PVDs rather than two clearly distinct entities. 11 According to the WSPH 2018, Group 1.6 PH is now called PAH with overt features of venous/capillary involvement (PVOD/PCH). 11 The prevalence for IPAH is 2.1−4.4 cases per million children, 12 but several-fold higher for PAH-CHD. PVOD/PCH was diagnosed in only 0.7%−2% of PAH cases in European pediatric registries, 12 and thus appears to be very rare. 4. Diagnostic methods and variables and their application in pediatric PH have been updated. In particular, the EPPVDN evaluated new echocardiographic surrogate variables for its use in pediatric PH (normal reference values by age and gender available). The diagnostic algorithm is shown in Figure 1 
Hemodynamic assessment and acute pulmonary vasoreactivity testing (AVT) in the evaluation of children with PH/PVD (cardiac catheterization)
The hemodynamic definition of PH, including sub-types of this heterogeneous condition, and its classification have been revised and updated recently. 11 The recommendations of the EPPVDN (2019) include these recent changes and continue to focus on the clinical implication of accurate hemodynamic assessment of children with PH/PVD ( Table 5 ). Newly derived data from pediatric studies and registries have been screened and are enclosed to support evidence-based performance of invasive hemodynamic assessment and AVT in children with PH. A detailed discussion on diagnostic cardiac catheterization in pediatric PH can be found elsewhere. 16 Use of cardiac magnetic resonance (CMR) and computed tomography (CT) in children with suspected or confirmed PH We introduce newly developed key variables such as the CTderived ratio of mean pulmonary artery to ascending aorta inner diameter that, when increased, raises the suspicion for pediatric PH (Table 6 ). Special attention is also given to CMR assessment of biventricular systolic function that may help to detect pathophysiologic processes associated with severe PH. Detailed protocols and the technical limitations of CT and CMR non-invasive imaging are discussed elsewhere. 19 
Suspicion of PH

Figure 1
Diagnostic algorithm for a child or young adult with suspected PH. Screening for pediatric PH is performed by ECG and echocardiography. If these investigations suggest the presence of PH/PHVD, chest X-ray and/or chest CT should be considered, followed by additional investigations. If PH/PHVD is severe, and the patient presents severely ill in overt heart failure and/or pulmonary vascular crisis, cardiac catheterization may be postponed and pharmacotherapy including intravenous prostanoids started immediately. CPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic thromboembolic pulmonary hypertension; CXR, chest X-ray; ECG, electrocardiogram; FC, functional class; HIV, human immunodeficiency virus; HPAH, heritable pulmonary arterial hypertension; HR, high resolution; IPAH, idiopathic pulmonary arterial hypertension; LFT, liver function test; MRI, magnetic resonance imaging; PCH, pulmonary capillary hemangiomatosis; PH, pulmonary hypertension; PHVD, pulmonary hypertensive vascular disease; PVOD, pulmonary veno-occlusive disease; VQ, ventilation/perfusion; WHO, World Health Organization. Modified from Lammers et al., 2016. 6 
Use of genetic counseling and testing and biomarkers in children with PH
We provide detailed recommendations on genetic testing in pediatric patients with PH and family members. In addition, we give recommendations for the determination of blood biomarkers at diagnosis and follow up ( Table 7) . 6 An algorithm on genetic counseling and testing for a child with IPAH or HPAH and his/her family members is presented in Supplementary Figure S2 online. A general discussion on genetic counseling/testing and biomarkers in pediatric PAH can be found elsewhere. 20 The WSPH 2018 task force on genetics and genomics in PH estimated that approximately 25%−30% of patients diagnosed with IPAH have an underlying Mendelian genetic cause for their condition and should more accurately be classified as HPAH (with an identified pathogenic gene variant). 21 Down syndromerelated PH varies in terms of etiology and severity, and-in the absence of CHD (Group 1 or Group 2)-should be classified as Group 3 PH (Supplementary Tables S1 and S10 online). 12 
Evaluation and management of PH in children and young adults with CHD (PAH-CHD and pulmonary hypertensive vascular disease [PHVD]−CHD)
We focus our recommendations on the operability and treatment of children with simple ( Figure 3 ) or complex CHD (Table 8 ). Special attention is given to a new treat-to-close (treat-and-repair) approach in highly selected patients with a pre-or post-tricuspid shunt from the grey zone (pulmonary vascular resistance index, 6−8 WU ¢m 2 ), that is, pre-
Figure 2
Determinants of risk in pediatric PH and suspected PHVD. Variables are listed that distinguish between lower risk and higher risk, while the intermediate risk group is broad and not specifically defined. Overall, these determinants have only level of evidence C because of sparse or lacking pediatric data. Healthcare providers may include here PVR/SVR ratio, the 6 minute walk distance, and VO 2max obtained during cardiopulmonary exercise testing as risk variables; however, it is unclear where exactly the cut-off values should be set. One must also note that most of these variables have been validated mostly for IPAH, and the cut-off levels used above may not necessarily apply to other forms of PAH. Furthermore, the use of approved therapies and their influence on the variables should be considered in the evaluation of the risk. See also supplementary Figure S1 for the EPPVDN risk score sheet (PH risk stratification). BMI, body mass index; BNP, brain natriuretic peptide; CI, cardiac index; CMR, cardiovascular magnetic resonance imaging; e.s., end-systolic; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; mSAP, mean systemic artery pressure; NT-proBNP, N terminal pro BNP; PAAT, pulmonary artery acceleration time by transthoracic Doppler echocardiography; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PHVD, pulmonary hypertensive vascular disease; PSAX, parasternal short axis view by transthoracic echocardiography; PVR, pulmonary vascular resistance; PVRi, pulmonary vascular resistance index; RA, right atrium; RV, right ventricle; S/D ratio, systolic/diastolic duration ratio by Doppler echocardiography; SVR, systemic vascular resistance; SVRi, systemic vascular resistance index; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; VO 2max , maximum rate of oxygen consumption; WHO, world health organization; WU, Wood unit. Modified from Hansmann et al., 2016. 14 operative mono-or dual PAH-targeted pharmacotherapy ( Figure 3 ). When PAH persists after cardiovascular shunt closure, patients with repaired CHD may be treated with a phosphodiesterase-5 inhibitor and/or endothelin receptor antagonist ( Supplementary Tables S4 and S5 online) . Complex heart diseases specific for the pediatric age group that are associated with congenital anomalies of the pulmonary vasculature, such as segmental PH, single ventricle physiology, and the scimitar syndrome, are listed in Supplementary  Table S7 online and often require an individualized, multidisciplinary approach. An individualized approach is also needed for congenital post-capillary obstructive lesions, such as pulmonary vein stenosis and small left-sided cardiac structures ( Supplementary Table S8 online), as well as for restrictive cardiomyopathy with isolated post-capillary PH or combined pre-and post-capillary PH ( Supplementary  Table S3 online). Further details on PH-CHD in children and young adults are discussed elsewhere. 3 
,22−24
Supportive measures and pharmacotherapy in PPHN and PH associated with bronchopulmonary displasia (BPD)/neonatal chronic lung disease (CLD)
In the following section, we provide practical recommendations on the treatment of infants with PH, including PPHN, BPD-PH, and neonatal CLD. In addition, we focus on supportive measures, monitoring, and diagnostics of infants with BPD-PH and PPHN (Table 9 ). A detailed discussion of and algorithms for the clinical management of PPHN
Figure 3
Algorithm for the management of patients with CHD associated with PAH/PHVD and congenital shunt lesions. The indication for invasive diagnostics and eligibility for surgery/operability by comprehensive right and left heart catheterization includes basic evaluation and AVT, the latter especially in the gray zone of forecast uncertainty. Red frames indicate likely inoperable. Green frames indicate operability (pursue complete shunt closure). Of note: This algorithm does not cover the difficult treatment of children and young adults with isolated or predominantly post-capillary PH because of post-capillary obstructive lesions, for example, in the setting of pulmonary vein stenosis, mitral stenosis or other small left-sided structures ( Supplementary Table S8 online), or cardiomyopathy with elevated left ventricular end-diastolic filling pressures. AVT, acute vasoreactivity testing; ASD, atrial septal defect; CHD, congenital heart disease; iNO, inhaled nitric oxide; PAH, pulmonary arterial hypertension; PDA, patent ductus arteriosus; PH, pulmonary hypertension; PHVD, pulmonary hypertensive vascular disease; pre-OP, preoperatively; PVR, pulmonary vascular resistance; PVRi, pulmonary vascular resistance index; Qp, pulmonary blood flow; Qs, systemic blood flow; SVR, systemic vascular resistance; VSD, ventricular septal defect; WU, Wood unit. Modified from Lopes and Barst and the Pulmonary Vascular Research Institute PAH-CHD taskforce (Pulmonary Vascular Research Institute website; published on September 26, 2013) and Kozlik-Feldmann et al., 2016. 22 ( Supplementary Table S9 online) and BPD-and CLD-PH ( Supplementary Table S10 online) can be found elsewhere. 25 Therapy of acute PH in the pediatric intensive care unit: Pharmacotherapy and mechanical circulatory support Management of children with PH can be be extremely challenging in the critical care setting. Children with pre-existing IPAH (acute-on-chronic) and those with PAH-CHD (e.g., peri-operatively) especially are high-risk populations. Basic management of critically ill patients with PH includes application of oxygen and treatment of triggering or aggravating factors such as acidosis, agitation, pain, volume overload or dehydration, arrhythmia, anemia, and infection. Targeted therapy to decrease the RV pressure afterload (Table 10 ) is accompanied by pharmacotherapy to increase myocardial perfusion and to counteract right-to-left interventricular septal shift.
Treatment of pediatric PH
PHVD and associated heart failure is complex, and the selection of appropriate therapies remains difficult in children and young adults. The so-called PAH-specific medications currently approved for therapy of adults with PAH target 3 major pathways (endothelin, nitric oxide, and prostacyclin). Moreover, some PH centers may use offlabel drugs for compassionate use in selected cases. Pediatric PAH therapy is largely based on expert experience Treatment algorithm for pediatric PAH. This algorithm applies to IPAH and HPAH (previously called familial PAH). Solid clinical data on the therapy of other forms of PH are limited, but the algorithm may apply to adult patients with DPAH. Initial monotherapy may be considered only when patient is at low risk (residual role for monotherapy). Monotherapy (e.g., with PDE-5i) in PAH-CHD after shunt closure and monotherapy (mostly with PDE-5i) in BPD-PH and CLD-PH is commonly used (residual role for monotherapy). We recommend initial upfront dual oral combination therapy (PDE-5i + ERA) when the patient is likely at intermediate risk. Dual oral therapy may be combined with inhaled, intravenous, or subcutaneous prostacyclin agonist (prostacyclin analogue), depending on risk stratification and clinical condition. Patients should be referred to a lung transplantation center for LuTx evaluation when they remain in an intermediateor high-risk category despite maximal PAH therapy. In experienced centers, the 1-year survival rates after LuTx now exceed 90%. A pretransplant rehabilitation program may be considered. Aside from sildenafil and bosentan (>1 year of age), all other agents are considered off-label drugs in children with PH in Europe. Sildenafil dosing recommendations should follow EMA-approved dosing for children. Bosentan received the following dual grading: COR I, LOE B for children with PAH and ES, and COR IIa, LOE C for children with PAH without ES. AVT, acute vasoreactivity testing; CCB, calcium channel blocker; COR, class of recommendation; DPAH, drug-induced pulmonary arterial hypertension; EMA, European Medicines Agency; ERA, endothelin receptor antagonist; ES, Eisenmenger syndrome; HPAH, heritable pulmonary arterial hypertension; inh., inhalation; IPAH, idiopathic pulmonary arterial hypertension; i.v., intravenously; LOE, level of evidence; PDE-5i, phosphodiesterase 5 inhibitor; s.c., subcutaneously. Children with suspected or confirmed PH should be evaluated and treated in specialized pediatric centers. I C The initial evaluation should include a comprehensive medical history, physical examination, assignment to a functional class, and assessment of cardiac function (ECG and echocardiogram). This should be followed by further diagnostic testing to delineate the PH etiology-ideally before the initiation of therapy. (S3-1−S3-5)
I B
A CXR is recommended at baseline with acceptable risk/radiation exposure. I C Regular CXRs at follow up visits are not indicated, unless there is a clinical reason (S3-6, S3-7).
III no benefit C Serial echocardiograms and ECGs are recommended every 3−6 months. In unstable or symptomatic patients or those who undergo therapeutic changes, more frequent echocardiograms may be indicated. 6MWT, six-minute walk test; COR, class of recommendation; CPET, cardiopulmonary exercise testing; CTEPH, chronic thromboembolic pulmonary hypertension; CXR, chest X-ray; DLCO, diffusing capacity of the lungs for carbon monoxide; HR-chest CT, high resolution chest computed tomography; ECG, electrocardiography; LOE, level of evidence; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PoPH, portopulmonary hypertension; PVD, pulmonary vascular disease; PVOD, pulmonary veno-occlusive disease; RSV, respiratory syncytial virus; VQ, ventilation-perfusion.
The above recommendations relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and were based on pediatric data only (COR, LOE). The grading and voting process within the writing group and the complete list of references (S3-1 to S3-30) on the above topic can be found in the Supplementary Material online. See also the diagnostic algorithm (Figure 1 ), determinants of risk ( Figure 2 ), algorithm on PAH-congenital heart disease (Figure 3 ), classifications (Supplementary Tables S1 and S2 online) and definitions ( Supplementary  Table S3 online). Specific recommendations on specific diagnostic tools are given in Tables 4−6. and trial data from adult studies; however, the first randomized pediatric PAH trials have been conducted recently. Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) is now considered within the spectrum of PAH, characterized by very pronounced venous/capillary involvement (Box 1), and as such is a condition that is associated with a particularly poor prognosis, very limited response to PAH therapy, and the risk of pulmonary edema with vasodilator therapy.
Here, we make recommendations (Table 11 ) on early combination therapy (double or triple) in PAH patients in WHO functional class II−IV, including those with inadequate response to the initial pharmacotherapy ( Figure 4 ; Supplementary Tables S4 and S5 ). In those patients with progressive, severe PAH and inadequate response to therapy, advances in drug development and both interventional and surgical procedures provide strategies to prevent, reverse, or ameliorate all, RV pressure overload, left ventricular compression/underfilling, and ultimately end-stage heart failure.
Diagnosis and management of PH in middle to low income regions (MLIRs)
In this section, we focus on diagnosis and management of PH in MLIRs where PH prevalence is high and etiology is broad. Special attention is given to the diagnosis of left heart disease (i.e., rheumatic heart disease), acquired lung diseases (i.e., tuberculosis), infections such as HIV and schistosomiasis, and unrepaired CHD. Additionally, we discuss operability in late-presenting patients with CHD and the role of phlebotomy in patients with Eisenmenger (Table 12 ). Recommendations covered in other sections (chest X-ray, electrocardiogram, pulse oximetry in 6-minute walk test, phlebotomy and anticoagulation in Eisenmenger patients, pregnancy counseling, and antibiotic prophylaxis for subacute bacterial endocarditis) are not mentioned in this table. So far, only very few registries exist worldwide that can provide useful information on PH in MLIRs (Supplementary Figure S3 online). The above recommendations relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and were based on pediatric data only (COR, LOE). The grading and voting process within the writing group and the complete list of references (S5-1 to S5-27) on the above subtopic can be found in the Supplementary Material online. For hemodynamic definitions, invasive measures and their clinical implications, see Supplementary Table S3 online. *It should be noted that the World Symposium on Pulmonary Hypertension 2018 has recommended the use of the Sitbon criteria for a positive AVT in children with IPAH/HPAH, as defined by a decrease in mPAP by at least 10 mm Hg to an mPAP value below 40 mm Hg without a fall in cardiac output. 12 However, most of the European Pediatric Pulmonary Vascular Disease Network's voting group found that there is insufficient evidence for such a recommendation in children and preferred to continue to recommend the modified Barst criteria that define a positive AVT, as outlined in the above table. It should also be noted that there is inaccuracy in the published literature on the cut off values that define the different types of PH (pre-capillary, isolated post-capillary, and combined pre-and post-capillary PH) and mPAP cut off values for AVT, mostly because of inaccurate use of mathematical symbols (> vs. ≥ and < vs. ≤). If deep sedation or general anesthesia is required for CMR in a child with PH, the risks and benefits of the diagnostic procedure must be critically reviewed in advance.
I C
It is recommended that a CMR study of a child with suspected PH should include the following modes of imaging ():
Cine CMR for the assessment of biventricular mass, volume, and function, using a stack of axial or short axis slices covering the entire heart. LGE can be beneficial for the identification and quantification of myocardial fibrosis. (S6-5) IIb C Regional RV myocardial function determination might be reasonable by CMR tagging techniques (uncertain yield).
IIb C Simultaneous CMR assessment of biventricular function and ECG may be useful to detect interventricular and LV dyssynchrony that have an impact on cardiac performance. The above recommendations relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and were based on pediatric data only (COR, LOE). The grading and voting process within the writing group and the complete list of references (S6-1 to S6-10) on the above sub-topic can be found in the Supplementary Material online. Genetic testing for the PAH-associated genes NOTCH3, SMAD9, GDF2, AQP1, SMAD8, SOX17, and ATP13A3 may be useful in children with PAH of unknown cause and identification of family members at risk, although further evidence is needed to confirm pathogenicity of these mutations. (S7-1), (S7-11)
IIb B
Children who are asymptomatic PAH mutation carriers should be screened with echocardiograms every 1−3 years for the presence of elevated RV pressure, and subsequently undergo additional diagnostic evaluation if clinically indicated.
I C
Genetic testing of first-degree relatives of an index patient with PAH and a known disease-causing mutation is indicated for risk stratification and rationalizing surveillance.
Asymptomatic first-degree relatives of patients with HPAH without an identified PAH-associated gene mutation should be screened with serial echocardiograms for the presence of elevated RV pressure, and subsequently undergo additional diagnostic evaluation if clinically indicated.
I C (continued) (Figure 3 and Table 5 ).
(S8-13) I C Children with PVRi ≥ 6 WU £ m 2 and a PVR/SVR ratio ≥ 0.3 should be evaluated by AVT (Figure 3 and Table 5 ). (S8-13, S8-17 ).
Individual patient assessment in tertiary pediatric PH centers is particularly needed when PVRi is between 6 and 8 WU £ m 2 (gray zone) ( Figure 3 and Table 5 ). (S8-13)
A treat-to-close (treat-and-repair) approach (defined as PAH-targeted pharmacotherapy with 1−2 medications followed by partial or complete defect closure) might be considered in highly selected patients with pre-or post-tricuspid shunt (ASD, VSD, PDA) from the gray zone (PVRi 6−8 WU £ m 2 ), and potentially even in children with PAH with PVRi > 8 WU x m 2 , with the goal to decrease PVRi << 8 WU x m 2 . After (complete or partial) closure, such patients must stay under long-term tertiary follow-up and be reassessed by cardiac catheterization, in addition to non-invasive measures, to assess for PVR after shunt closure. (S8-13, S8-18)
IIb C
A partial defect closure (fenestrated patch or device) may be considered in selected patients with PAH-CHD from the gray zone (PVRi 6−8 WU £ m 2 ), with or without preceding treat-to-close (treat-and-repair) approach. The impact of PVR numbers alone for clinical decision making differs between patients at different ages (e.g., infants with VSD vs young adults with ASD). (S8-18−S8-20)
Alternatively, PA banding may be considered in selected patients with PAH-CHD with a large post-tricuspid shunt (VSD, complete AVSD = complete AVC) as an alternative to partial defect closure, especially when there is complex cardiac anatomy (e.g., straddling AV-valve) in infancy or significant comorbidity (e.g., genetic syndrome). In children/young adults with total cavopulmonary connection (Fontan) and symptoms-irrespective of hemodynamics (mTPG)-targeted PH therapies (ERA, PDE-5i, inhaled iloprost) may be considered to improve exercise capacity. (S8-1, S8-44−S8-47) IIb C ASD, atrial septal defect, AV, atrioventricular; AVC, atrioventricular canal; AVSD, atrioventricular septal defect; AVT, acute vasoreactivity testing; CoA, coarctation of the aorta; CHD, congenital heart disease; ERA, endothelin receptor antagonist; LV, left ventricle; LVOTO left ventricular outflow tract obstruction; mTPG, mean transpulmonary gradient; PA, pulmonary artery; PAH, pulmonary arterial hypertension; PAH-CHD, pulmonary arterial hypertension with congenital heart disease; PaO 2 , partial pressure of oxygen; PDE-5i, phosphodiesterase-5 inhibitor; PDA, persistent ductus arteriosus; PH, pulmonary hypertension; PHVD, pulmonary hypertensive vascular disease; PHVD-CHD, pulmonary hypertensive vascular disease with congenital heart disease; PVD, pulmonary vascular disease; PVR, pulmonary vascular resistance; PVRi, pulmonary vascular resistance index; Qp, pulmonary flow; Qs, systemic flow; RV, right ventricle; SpO 2 , peripheral capillary oxygen saturation; SVR, systemic vascular resistance; TPG, transpulmonary gradient; TTE, transthoracic echocardiography; VSD, ventricular septal defect; WU, Wood unit.
IIb
The above recommendations relate to the grading system currently suggested by the European Society of Cardiology and the American Heart Association and were based on pediatric data only (COR, LOE). The grading and voting process within the writing group and the complete list of references (S8-1 to S8-47) on the above sub-topic can be found in the Supplementary Material online. An algorithm for the management of PAH-CHD and a tabular list of PAH medications is provided in Figure 3 and Supplementary Table S5 online. 
IIb B
Intratracheal surfactant should be considered for the preterm and term neonate with PPHN and pulmonary diffusion impairment (but without congenital diaphragmatic hernia) to optimize ventilation and oxygenation (e.g., a newborn with meconium aspiration syndrome and PPHN). (S9-4, S9-5)
IIa B
It is not well established that iNO in preterm infants below 34 weeks of gestation with respiratory failure reduces the incidence of BPD (S9-6).
IIb C iNO administration may be considered in preterm infants below 34 weeks of gestation with respiratory failure and confirmed PH. (S9-7)
IIb C iNO is indicated for treatment of PPHN in mechanically ventilated term and near-term newborn infants to improve oxygenation and to reduce the need for ECMO (i) if PaO 2 is less than 100 mm Hg (while receiving 100% oxygen) or The preterm and term neonate with severe PH (PPHN) should receive PGE1 or PGE2 to maintain ductal patency in right heart failure, in the absence of a significant post-tricuspid unrestrictive shunt (e.g., large VSD). 
Recommendations
COR LOE Oxygen should be given when the transcutaneous oxygen saturation is < 95% in children with PH and normal cardiac anatomy.
I C
Intravenous prostanoids should be considered to treat children with severe PH. (S10-1, S10-2) IIa B iNO may be considered for treatment of post-operative PH in mechanically ventilated patients to improve oxygenation and reduce the risk of pulmonary hypertensive crisis. (S10-3, S10-4)
IIb B
Concomitant sildenafil should be administered to prevent rebound PH in patients who have signs of increased PAP on withdrawal of iNO and require restart of iNO despite preceding gradual weaning of iNO. (S10-5−S10-8)
I B
Oral tadalafil can be considered as a therapeutic alternative to oral sildenafil in infants and children with signs of increased PAP (see recommendation above). (S10-9)
IIb B
Intravenous sildenafil may be considered for treatment of PH in critically ill patients, especially in those with an unsatisfactory response to iNO. (S10-8) Intravenous sildenafil reduced PAP and shortened time to extubation and ICU stay in children with post-operative PH. (S10-8)
IIb C
Inhaled iloprost may be as effective as iNO in children with post-operative PH. (S10-10−S10-12) IIb B In children who develop signs of low cardiac output or profound pulmonary failure despite optimal medical therapy, extracorporeal life support may be considered as bridge to transplantation or recovery. (S10-13)
IIb C COR, class of recommendation; ICU intensive care unit; iNO, inhaled nitric oxide; LOE, level of evidence; PAP, pulmonary artery pressure; PH, pulmonary hypertension.
This table summarizes the actual treatment recommendations of acute PH in the pediatric ICU. The above recommendations of the European Pediatric Pulmonary Vascular Disease Network relate to the grading system by the European Society of Cardiology and the American Heart Association and are based on pediatric data only (COR, LOE). The complete list of references (S10-1 to S10-13) on the above sub-topic can be found in the Supplementary Material online. < 60 mm Hg (S11-1)
IIa C
Oxygen can be particularly useful for children with PH and an element of parenchymal/interstitial lung disease (e.g., bronchopulmonary dysplasia/neonatal CLD). (S11-2)
IIa B
Oxygen may be useful for patients with an intrapulmonary shunt and important for PH patients while at altitude or during air travel.
IIb C
Based on PAH and heart failure studies in adults, mineralcorticoid receptor blockade with spironolactone or eplerenone may be beneficial in PAH patients by improving RV and LV diastolic function. No data or significant experience on eplenerone in children with PAH are available. (S11-3−S11-5)
Diuretic therapy may be considered for selected pediatric patients with PH, that is, those with confirmed fluid overload and/or significant left-to-right shunt.
Diuretic therapy should be initiated cautiously because patients with PH and high PVR often are pre-load dependent to maintain an optimal cardiac output. (S11-4)
I C
The benefit of chronic anticoagulation (warfarin, phenprocoumon) in children with PAH is unclear (so far not studied in children).
IIb C
Chronic anti-coagulation can be useful in patients with progressive IPAH/HPAH (empirical goal Rs 2.0-INR2.5), patients with CTEPH, patients in low cardiac output, and those with hypercoagulable states.
IIa C
Indication for anti-coagulation should be critically reviewed, especially in small children prone to hemorrhagic complications. In these cases, anti-platelet therapy (e.g., ASA) may be an alternative.
IIb C
Anti-coagulation, but also anti-platelet therapy (e.g., ASA), should be very critically reviewed in those children prone to hemorrhagic complications because of platelet dysfunction, such as congenital or acquired von Willebrand syndrome (flow/shear stressed induced hemostatic defects), or concomitant PCA therapy (IV/SC treprostinil or IV epoprostenol), as anti-coagulation or anti-platelet therapy may cause harm in these settings. (S11-6)
III harm C Accordingly, anti-coagulation is potentially harmful in children with HHT or portopulmonary hypertension. III harm C Before starting PAH-targeted therapy for chronic PH, vasodilator responsiveness should be determined by cardiac catheterization; particularly, anatomical obstruction from pulmonary venous disease or from left-sided heart disease should be excluded in this setting. (S11-4, S11-7)
I C CCB: Treatment with CCB (either as monotherapy or in combination with other PAH drugs) should be considered in those patients who have previously been shown to be acutely reactive to iNO § oxygen during AVT (AVT responders). (S11-7)
IIa C For children with a negative acute vasoreactivity response, or in those with a failed or non-sustained response to CCBs, risk stratification should probably determine additional PAH-targeted therapy. (S11-7, S11-8)
IIa C
CCBs are contraindicated in children who have not undergone AVT, in proven non-responders to acute vasodilator testing, and in those with right heart failure, regardless of AVT response. (S11-7, S11-9−S11-11) III harm C Children with PAH and a significant intracardiac left-to-right shunt, and those with Eisenmenger syndrome (i.e., suprasystemic PVR and right-to-left shunt), most likely do not benefit from CCB therapy, regardless of acute vasodilatory response or severity of PHVD, and thus, CCBs are not useful in this setting. (S11-7, S11-9, S11-10)
III no benefit C Most children with severe PAH are non-responsive to AVT (iNO § oxygen) and should receive targeted therapy other than CCBs. (S11-8, S11-9) I C
In the child with mild to moderate chronic PH and lower risk (Figure 2) , initiation of oral goal-targeted therapy is recommended (Figure 4 ), regardless of a negative acute vasoreactivity response, and should begin with either a PDE-5i or an ERA, or a combination of PDE-5i and ERA ( Supplementary Table S5 ). (S11-9, S11-12)
I C
Oral sildenafil can be useful in the setting of iNO weaning in post-operative PH, or in the presence of PH related to parenchymal/interstitial lung disease. (S11-13, S11-14)
IIa B
High dose oral sildenafil treatment (defined in the STARTS-1/-2 trials), either as monotherapy or add-on drug, was associated with a higher mortality rate in children (>8 kg, >1 year old) with PAH/PHVD, including potentially increased mortality. (S11-9, S11-14, S11-15) III harm B IV sildenafil may be considered in neonates with PPHN treated with or without iNO. (S11-16, S11-17) IIb C IV sildenafil may be considered in children with CHD and post-operative PAH/intermittent pulmonary hypertensive crisis, on or off iNO. (S11-9, S11-18)
Early combination therapy with two oral PAH-targeted drugs in newly diagnosed (treatment-naive) children with PAH in WHO functional class II-III is reasonable. (S11-9)
IIa C
In severe (WHO functional class IV) and/or rapidly progressive PAH (diagnosed by cardiac catheterization and non-invasive imaging), continuous IV PCA therapy (i.e., epoprostenol or treprostinil) should be started without delay (start with prostanoid monotherapy or dual/triple combination therapy including PCAs). (S11-9, S11-19−S11-21) Recommendations COR LOE Start of PCA therapy with IV treprostinil or IV iloprost instead of epoprostenol can be considered in certain circumstances. (S11-9, S11-22, S11-23)
IIa C SC PCA therapy (SC treprostinil) may be beneficial in children with severe PAH. (S11-24) IIa B Combination of IV (e.g., epoprostenol or treprostinil) or SC PCAs (treprostinil) with 1 or 2 oral PAH-targeted drugs (e.g., sildenafil, bosentan) may result in better long-term survival in patients with severe PAH.
IIb C
iNO is mainly used in the ICU setting and useful in patients with acute pulmonary vascular crisis and/or acute exacerbation of PH in the setting of an underlying parenchymal lung disease and/or PPHN. (S11-9, S11-25−S 11-27) I B
During the weaning phase of iNO, PH rebound may occur that can be prevented through concomitant use of oral or IV sildenafil administration. (S11-28)
I B
Atrial septostomy (AS), with or without device implantation, preferably resulting in a restrictive interatrial communication, may be considered in patients in functional class III and IV and recurrent syncope under combined medical therapy and as palliative bridge to transplant, increasing the chance for survival while waiting for a donor organ. (S11-29−S11-32) This table summarizes the current recommendations for the treatment of pediatric PH. The above recommendations of the European Pediatric Pulmonary Vascular Disease Network relate to the grading system by the European Society of Cardiology and the American Heart Association and are based on pediatric data only (COR, LOE). The grading and voting process within the writing group and the complete list of references (S11-1 to S11-39) on the above sub-topic can be found in the Supplementary Material online. For pharmacotherapy, see also Supplementary Table S5 online. Treatment of (i) PAH-CHD (Table 8 , Figure 3 ), (ii) CLD-PH/BPD-PH (Table 9) , and (iii) acute PH in the ICU, including mechanical circulatory support (Table 10 , Supplementary  Table S4 online), are discussed in separate sections of this consensus statement. Recommendations COR LOE Patients with HIV infection and PH documented by echocardiography may benefit from PAH-specific therapy (especially bosentan). The role of HAART on the prevalence and outcome of PH secondary to HIV is still controversial. (S12-8−S12-10) I C Treatment with PAH-specific medication (especially sildenafil) in patients with SCD-related PH is controversial and may lead to increases in SCD-related vaso-occlusive crisis. (S12-11) III harm C Patients living at high altitude with symptoms and signs of PH may undergo a detailed transthoracic echocardiogram to detect PH.
I C
The initial patient history needs to include all major socioeconomic determinants of compliance (profession, family structure, and proximity to treating center). Such information is critical to determine the compliance to treatment and subsequent follow-ups in PH patients. (S-12-2) I C Patients with high altitude−related PH may benefit from PAH-specific medications. (S12-12) IIa B Children < 2 years of age living in MLIRs with PH and so-called simple shunts (ASD, VSD, or PDA) who have normal saturations, signs of increased pulmonary blood flow, and exclusive left-to-right shunt on echocardiography may undergo shunt closure without invasive hemodynamic evaluation. (S12-13, S12-14)
IIb C
In children with cardiovascular shunt lesions, non-invasive oxygen saturations and arterial PaO 2 during exercise should be measured. A drop in PaO 2 of > 10 mm Hg or SpO 2 by 19% during exercise may indicate an inoperable shunt because of increased PVR. (S12-13−S12-15) I C A comprehensive echocardiogram at diagnosis is recommended as this is the main (and may be the only) modality of diagnosing PH. Features of operability in shunt lesions should also be assessed using echocardiogram. Serial echocardiograms and ECGs may not be feasible in MLIRs (because of lack of expertise and equipment) or cost effective and may be performed on a case-to-case basis. (S12-2, S12-3, S12-16)
I B
Further imaging (mainly chest CT) is recommended to exclude underlying parenchymal/interstitial lung disease, in ex-premature infants, and in patients with BPD, Down syndrome, or other well-known risk factors. (S12-1, S12-2, S12-13)
Cardiac catheterization for diagnosis or routine follow-up needs to be done in PH centers only. Lack of expert centers and standardization of cardiac catheterization in MLIRs may lead to erroneous data, wrong data interpretation, or little management value. In absence of vasoreactivity testing, the value of cardiac catheterization (especially if done for shunt operability) is limited. (S12-2, S12-3, S12-17, S12-18)
IIa B
If no underlying cause of PH is evident, specific tests for HIV, schistosomiasis, and chronic hepatitis (HBV and HCV) should be performed. An abdominal ultrasound is indicated to rule out liver cirrhosis and/or portal hypertension. (S12-2, S12-3, S12-19)
I B
Serial 6MWTs should include pulse oximetry and are recommended to assess exercise tolerance and response to therapy, and to estimate prognosis in children with PH capable of performing such studies. 6MWT is an inexpensive, reproducible measure of functional capacity. Equipment and expertise for CPET are rarely available in MLIRs. (S12-20)
I C PAH-specific therapy is recommended and can significantly improve quality of life. Safety of intravenous therapy in a low-resource setting is also of concern (higher risk of infection and catheter-based complications). Inhalation therapies are often ineffective because of lack of sufficient patient compliance and/or difficulties with applying the devices at home. (S12-2, S12-3, S12-21)
For children with PH/PHVD undergoing surgery or other interventions requiring sedation or general anesthesia, consultation with cardiac anesthesia and PH service and appropriate post-procedure monitoring is required.
(S12-22, S12-23) I C Atrial septostomy and other surgical measures (e.g., reverse Potts shunt) and interventional procedures (ductal stenting, balloon atrioseptostomy) may be considered in highly selected cases at very few specialized centers. These procedures are risky per se and especially in MLIRs, with inconclusive long-term benefits especially in absence of a lung transplant program. (S12-24, S12-25)
IIb C Serial measurements of serum NT-proBNP concentration are indicated as changes in NT-proBNP reflect hemodynamic impairment. Cost-benefit assessment of this test is needed in MLIR health care settings. (S-12-26)
Limitations of the 2019 EPPVDN consensus statement on pediatric PH
We acknowledge that most LOE grades of our recommendations on pediatric PH are LOE B or C. Indeed, very few randomized controlled trials have been conducted so far because of the heterogeneity of what is still considered a rare-but underdiagnosed-heterogenous disease in high-income countries. We did discuss the specific complexity of pediatric PH and PAH-CHD in this guideline document. Challenges and future directions in the field (see Box 3) may differ by institution depending on the environment, particularly the medical and economic resources.
Conclusions
This guideline document provides a specific, comprehensive, practical framework for the best clinical care for children and young adults with PH of different etiologies. Although we obtained an increasing set of pediatric data from patient registries and clinical studies and derived conclusions from adult PAH trials, there are still important gaps of knowledge in the field. Nevertheless, advanced therapies, including combination pharmacotherapy and catheter and surgical interventions, are available to children with progressive/severe PAH. Regional differences in the etiology of PH make this a relatively frequent condition in middle to low income regions in which underdiagnosed congenital or acquired cardiac diseases often lead to Eisenmenger syndrome or post-capillary PH in children and young adults. For this reason, it is of utmost importance to raise awareness of pediatric PH in these parts of the world. The high morbidity and mortality, together with the high prevalence of severe PH in such regions with accelerated population growth, underline not only the health care burden but also the unmet need to improve early diagnosis and proper, goal-directed treatment of PH in the young globally.
Take-home messages
The 2019 updated consensus statement of the EPPVDN makes recommendations on established and newly identified diagnostic and monitoring variables, tools, and procedures in pediatric PH. New predictors of outcome have been defined that characterize a child with PH at higher risk (pediatric determinants of risk). In particular, WHO functional class, N-terminal prohormone of brain natriuretic peptide, and tricuspid annular plane systolic excursion have been identified as surrogate variables for survival and thus can serve as treatment goals. A simplified adult PAH risk score based on the 2015 ESC/ERS guidelines emphasizes particularly the prognostic value of mean right atrial pressure, cardiac index, WHO functional class, and N-terminal prohormone of brain natriuretic peptide. A composite end point that consists of death, lung transplantation, or significant disease progression (defined as unplanned PAH-related hospitalization, initiation of intravenous/subcutaneous prostacyclin analogue therapy, and/or WHO functional class deterioration) is probably a feasible end point for clinical trials in pediatric PH. Children with IPAH or HPAH (no significant CHD-shunt) who are true responders to AVT should be treated with calcium-channel blockers (CCBs) such as amlodipine; it should be noted that in patients with poor cardiac function, CCBs should not be used. Close long-term follow-up is required, and combination therapy may be warranted once CCB monotherapy becomes partly inefficient. The evolving strategy of upfront (or early rapid sequence) combination pharmacotherapy may further Box 3. Challenges and future directions for clinical research in pediatric PH
